66
Participants
Start Date
August 31, 2025
Primary Completion Date
August 31, 2028
Study Completion Date
December 31, 2028
KC1086
"Part 1: Dose-escalation phase , five dose groups are included: 1 mg, 2 mg, 4 mg, 6 mg, and 8 mg.~Part 2: Dose-expansion phase, 2 to 3 dose levels will be selected for expansion based on the results of the dose escalation phase."
Beijing Konruns Pharmaceutical Co., Ltd.
INDUSTRY